1
artículo
The aim of this paper is to provide a general overview of the rules of Private international law inthe European Union that deal with international contracts. The first part of the paper focuses on the analysis of the rules of Regulation 1215/2012 (Brussels I) that determine the international jurisdiction of the courts of the Member States to hear about contractual disputes. For this pur- pose a distinction is made between situations in which the parties have made use of forum-choice clauses and situations in which this has not been the case. The second part analyses Regulation 593/2008 (Rome I) on the law applicable to contractual obligations. As in the previous section, a distinction is made on whether the parties have agreed on the applicable law or not. This part also includes an analysis of the mechanisms in the Regulation allowing Member States to saveguardtheir national or E...
2
artículo
The aim of this paper is to provide a general overview of the rules of Private international law inthe European Union that deal with international contracts. The first part of the paper focuses on the analysis of the rules of Regulation 1215/2012 (Brussels I) that determine the international jurisdiction of the courts of the Member States to hear about contractual disputes. For this purpose a distinction is made between situations in which the parties have made use of forum-choice clauses and situations in which this has not been the case. The second part analyses Regulation 593/2008 (Rome I) on the law applicable to contractual obligations. As in the previous section, a distinction is made on whether the parties have agreed on the applicable law or not. This part also includes an analysis of the mechanisms in the Regulation allowing Member States to saveguardtheir national or EU i...
3
artículo
Publicado 2018
Enlace
Enlace
Purpose: Triple-negative breast cancer (TNBC) requires the iden- tification of reliable predictors of response to neoadjuvant chemotherapy (NACT). For this purpose, we aimed to evaluate the performance of the TNBCtype-4 classifier in a cohort of patients with TNBC treated with neoadjuvant carboplatin and docetaxel (TCb).Methods: Patients with TNBC were accrued in a nonrandomized trial of neoadjuvant carboplatin AUC 6 and docetaxel 75 mg/m2 for six cycles. Response was evaluated in terms of pathologic complete response (pCR, ypT0/is ypN0) and residual cancer burden by Symmans and colleagues. Lehmann's subtyping was performed using the TNBCtype online tool from RNAseq data, and germline sequencing of a panel of seven DNA damage repair genes was conducted.Results: Ninety-four out of the 121 patients enrolled in the trial had RNAseq available. The overall pCR rate was 44.7%. Lehmann subtype ...
4
artículo
Publicado 2018
Enlace
Enlace
Purpose: Prognostic value of pathologic complete response (pCR) and extent of pathologic response attained with anthracycline-free platinum plus taxane neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is unknown. We report recurrence-free survival (RFS) and overall survival (OS) according to degree of pathologic response in patients treated with carboplatin plus docetaxel NAC. Patients and methods: One-hundred and ninety patients with stage I-III TNBC were treated with neoadjuvant carboplatin (AUC6) plus docetaxel (75 mg/m2) every 21 days × 6 cycles. pCR (no evidence of invasive tumor in breast and axilla) and Residual cancer burden (RCB) were evaluated. Patients were followed for recurrence and survival. Extent of pathologic response was associated with RFS and OS using the Kaplan-Meier method. Results: Median age was 51 years, and 52% were node-positive. pCR and ...
